RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.

About the Regulatory Profession

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Regulatory Code of Ethics

One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.

Regulatory Competency Framework

Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.

Regulatory Convergence

Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.

Development of Painkillers Focus of New FDA Draft Guidance

Extensive new draft guidance released this week by the US Food and Drug Administration (FDA) makes formal recommendations on how sponsors of analgesic painkillers should develop their products in preparation for eventual marketing authorization.

All three types of pain-acute, chronic and breakthrough-are characterized by the need for long-term, regular treatment with analgesics. FDA notes that while it is important to understand how a single dose of the drug works, it's even more interested in understanding how the drug functions as part of a long-term regimen.

Draft Guidance

The guidance contains a plethora of advice for companies seeking ultimate approval.

"Specifically, this guidance focuses on drug development and trial design issues and chemistry, manufacturing, and controls concerns that are unique to the study of acute, chronic, and breakthrough pain and the labeling considerations for analgesic drugs," FDA explained in the preamble of the guidance.

One early consideration noted by FDA is the type of pain indication being sought by a sponsor. Regulators recommended that sponsors meet with FDA prior to the initiation of a Phase 3 clinical study to discuss proposed indications and whether or not they are feasible to obtain.

From there, FDA recommends four general approaches based on a novelty scale ranging from the newest drugs (i.e. New Molecular Entities), to reformulated drugs, add-on indications and additional claims.

Those approaches are then broken down by the type of pain experienced by patients, with FDA recommending specific approaches for each.

The guidance also speaks to various stages of clinical development, including the considerations each stage of a clinical trial should take into account with respect to safety, endpoints, patient populations, trial designs, routes of drug administration and more.